| Abstract: | Cytochrome P450 mono-oxygenases (2UUQ) enzyme from Mycobacterium tuberculosis catalyzes oxidation of organic compounds
such as lipids and steroidal hormones therefore remain as potential drug target. Currently available first line anti-tuberculosis
drugs have been caused several side effects in the body as well as resistance development by mycobacterium against these drugs,
necessitates the considerable need for finding new drugs. Therefore, we propose a structure based computational method to find a
new potential inhibitor for cytochrome P450 mono-oxygenases enzyme. Compounds from several ligand databases were docked
against the functional sites of 2UUQ (A) through the standard GEMDOCK v2.0 and AUTODOCK4.0 molecular docking tools.
Commercially available chemical compound ZINC00004165 (5-3-(2-nitroimidazol-1-yl) propyl] phenanthridine) has produced top
rank with lowest interaction energy of -113.2 (via GEMDOCK) and lowest docking energy of -9.80 kcal/mol (via AUTODOCK) as
compared to first line anti TB compounds. Z score and normal distribution analysis verified that the ZINC00004165 compound has
more affinity towards 2UUQ in comparison to large number of random population of compounds. ZINC00004165 is also in
agreement with the drug likeness properties of Lipinski rule of five without any violation. Therefore, our finding concludes that the
commercial compound ZINC00004165 can act as a potential inhibitor against cytochrome P450 mono-oxygenases enzyme of
Mycobacterium tuberculosis. |
